Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C (2020) Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 39:126. https://doi.org/10.1186/s13046-020-01629-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940–952. https://doi.org/10.1016/S1470-2045(18)30351-6

Article  PubMed  Google Scholar 

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38:193–202. https://doi.org/10.1200/JCO.19.01307

Article  CAS  PubMed  Google Scholar 

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23:77–90. https://doi.org/10.1016/S1470-2045(21)00604-5

Article  CAS  PubMed  Google Scholar 

Sun B, Zhang L, Sun T, Ren Y, Cao Y, Zhang W, Zhu L, Guo Y et al (2022) Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a two-center retrospective study. Front Oncol 12:982948. https://doi.org/10.3389/fonc.2022.982948

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, et al. Lenvatinib plus camrelizumab vs. lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Front Oncol. 2022;12:809709. https://doi.org/10.3389/fonc.2022.809709

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, Guo RP (2021) Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol 11:618206. https://doi.org/10.3389/fonc.2021.618206

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Zhang Q, Mei J, Yang Z, Chen M, Liang T (2022) Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer 22:293. https://doi.org/10.1186/s12885-022-09405-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681–693. https://doi.org/10.1016/j.jhep.2021.11.018

Article  PubMed  Google Scholar 

Liu Q, You N, Li J, Wu K, Peng X, Wang Z, Wang L, Zhu Y et al (2021) Camrelizumab plus sorafenib versus sorafenib monotherapy for advanced hepatocellular carcinoma: a retrospective analysis. Front Oncol 11:694409. https://doi.org/10.3389/fonc.2021.694409

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J et al (2023) Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 24:1399–1410. https://doi.org/10.1016/S1470-2045(23)00469-2

Article  CAS  PubMed  Google Scholar 

Wang XH, Liu CJ, Wen HQ, Duan XH, Jiao YQ, Liu YJ, Chen MS, Zhu KS et al (2023) Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clin Transl Med 13:e1214. https://doi.org/10.1002/ctm2.1214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F et al (2023) Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer 180:9–20. https://doi.org/10.1016/j.ejca.2022.11.017

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1

Article  CAS  PubMed  Google Scholar 

Zhao Y, Zhang YN, Wang KT, Chen L (2020) Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 1874:188391. https://doi.org/10.1016/j.bbcan.2020.188391

Article  CAS  PubMed  Google Scholar 

Xing R, Gao J, Cui Q, Wang Q (2021) Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol 12:783236. https://doi.org/10.3389/fimmu.2021.783236

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Hu H, Yuan X, Fan X, Zhang C (2022) Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma. Front Immunol 13:896752. https://doi.org/10.3389/fimmu.2022.896752

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mei Z, Gao X, Pan C, Wu Q, Wang S, Qian J, Xu Z, Xu K et al (2023) Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2. Cancer Sci 114:1284–1296. https://doi.org/10.1111/cas.15719

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S et al (2019) Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE 14:e0212513. https://doi.org/10.1371/journal.pone.0212513

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuwano A, Yada M, Miyazaki Y, Tanaka K, Kurosaka K, Ohishi Y, Masumoto A, Motomura K (2023) Tumor-infiltrating CD8(+) T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma. Oncol Lett 25:259. https://doi.org/10.3892/ol.2023.13845

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L, Zhang Y, Duan Y et al (2020) Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer 9:338–357. https://doi.org/10.1159/000505695

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B (2021) The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 10:7977–7987. https://doi.org/10.1002/cam4.4312

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ouyang T, Kan X, Zheng C (2022) Immune checkpoint inhibitors for advanced hepatocellular carcinoma: monotherapies and combined therapies. Front Oncol 12:898964. https://doi.org/10.3389/fonc.2022.898964

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN et al (2021) Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma 8:1233–1240. https://doi.org/10.2147/JHC.S332420

Article  PubMed  PubMed Central  Google Scholar 

Xiang YJ, Wang K, Yu HM, Li XW, Cheng YQ, Wang WJ, Feng JK, Bo MH et al (2022) Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatini